MedTrace Logo

Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease

NCT07174076 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-09-15

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if cordyceps sinesis capsule (Bailiing Capsule) works to prevent the recurrence of microbiologically cured mycobacterium avium complex pulmonary disease in adults. The main questions it aims to answer are:

Does cordyceps sinesis capsule (Bailiing Capsule) prevents the recurrence of mycobacterium avium complex pulmonary disease in adults? Researchers will compare cordyceps sinesis capsule (Bailiing Capsule) to a placebo (a look-alike substance that contains no drug) to see if cordyceps sinesis capsule helps to prevent the recurrence of mycobacterium avium complex pulmonary disease.

Participants will:

Take cordyceps sinesis capsule (Bailiing Capsule) or a placebo (a look-alike substance that contains no drug) for 12 months, both are administered every day.

Visit the clinic once every 3 months for checkups and tests. Take online questionnaires every month.

Conditions

  • Mycobacterium Avium Complex Pulmonary Disease

Interventions

DRUG

cordyceps sinesis capsule

cordyceps sinesis capsule 4 capsules tid po for 12 months

DRUG

cordyceps sinesis capsule placebo

cordyceps sinesis capsule placebo 4 capsules tid po for 12 months

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Jiangxi Chest Hospital

    collaborator UNKNOWN

  • Guangzhou Chest Hospital.

    collaborator UNKNOWN

  • Anhui Chest Hospital

    collaborator OTHER

  • Beijing Chest Hospital

    collaborator OTHER

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Bin Cao

    lead OTHER

Principal Investigators

  • Xiaojing Cui, M.D. · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-24
Primary Completion
2028-07-24
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07174076 on ClinicalTrials.gov